Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Trifarotene significantly reduced inflammatory lesion count (Mean Difference: -11.5, 95% CI (confidence interval): -14.39 to -8.62) and non-inflammatory lesion count (Mean Difference: -12.25, 95% CI: -15.21 to -9.29), with a treatment success rate of 65.1% for facial acne and 66.9% for truncal acne in a 52-week Phase III (Investigator Global Assessment [IGA] rating of no or almost no acne) trial.
• In patients aged 12-17 with moderate acne, trifarotene was effective on both the face and trunk, with no significant differences in efficacy compared to clascoterone and tazarotene after 12 weeks of treatment.
• Overall treatment success rate was 57.9%, with improvements in quality of life (52.8% of patients achieving a Dermatology Quality of Life Index score of 0 or 1, compared to 22.6% at baseline).
• Trifarotene was well tolerated, with a low and acceptable rate of adverse events in two Phase 3 pivotal trials. Common adverse effects included pruritus, irritation, and sunburn.
• Differences in safety profiles between trifarotene, clascoterone, and tazarotene were suggested, though specific safety outcomes were not detailed in the systematic review.
• There is no specific subgroup information available beyond the age group of 12-17 years in the reviewed studies.